ABBVIE, INC. for ABBVIE INC.
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Trans-Atlantic Trade and Investment Partnership; Trans-Pacific Partnership Agreement; Colombia OECD Accession; Renewed engagement possibilities with Argentina; Colombia Special 301 Out-of-Cycle Review; Saudi Arabia recent developments report to USTR;
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL BACHNER | — |
| MICHAEL D BOYD | — |
| JOHN P. FORD | — |
| STEPHEN SCANGO | — |
| HEATHER STRAWN | — |
Copyright/Patent/Trademark CPT
H.R. 406 & S. 1767, Combination Drug Development Incentive Act of 2015; S. 1878, Advancing Hope Act of 2015; S. 632, STRONG Patents Act of 2015; H.R. 9, Innovation Act; S. 2733, Venue Equity and Non-Uniformity Elimination Act of 2016; H.R. 971 & S. 1421, Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015; H.R. 5573 & S. 3094, Price Relief, Innovation, and Competition for Essential Drugs (PRICED) Act; S. 3056, CREATES Act of 2016; Proposals/Initiatives related to international intellectual property protection;
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL BACHNER | — |
| MICHAEL D BOYD | — |
| JOHN P. FORD | — |
| ANDREW KAPLAN | — |
| HEATHER STRAWN | — |
Health Issues HCR
H.R. 6, 21st Century Cures Act; S. 2700, FDA and NIH Workforce Authorities Modernization Act; Discussions to clarify or reform the 340B program; Biologics Price Competition and Innovation Act; H.R. 1101 & S. 1287, Viral Hepatitis Testing Act; Public Law 111-148, The Patient Protection and Affordable Care Act; H.R. 2228 & S.122, Safe and Affordable Drugs from Canada Act of 2015; Proposals to address prescription drug abuse; Implementation/Reauthorization of The Prescription Drug User Fee Act (PDUFA); Implementation/Reauthorization of The Biosimilars User Fee Act (BsUFA); H.R. 639 & S. 481, Improving Regulatory Transparency for New Medical Therapies; H.R. 2570 & S. 1396, Value-Based Insurance Design Seniors Copayment Reduction Act of 2015; H.R. 3677 Opioid Abuse Prevention and Treatment Act of 2015; S. 524, Comprehensive Addiction and Recovery Act of 2016; H.R. 3012 & S. 2912, Trickett Wendler Right to Try Act of 2016; H.R. 6043 & S. 3335, Fair Accountability and Innovative Research Drug Pricing Act of 2016; H.R. 6174, Closing Loopholes for Orphan Drugs Act; S.3239, RACE for Children Act; Expanded Access (legislation not introduced); H.R. 4207, Medicare Fair Drug Pricing Act of 2015; Clinton's 1993 Health Security Act;
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL D BOYD | — |
| JOHN P. FORD | — |
| ANDREW KAPLAN | — |
| STEPHEN SCANGO | — |
| HEATHER STRAWN | — |
Budget/Appropriations BUD
H.R. 4974 & S. 2806, Military Construction and Veterans Affairs and Related Agencies Appropriations Act, 2017; P.L. 114-113, Consolidated Appropriations Act, 2016 (H.R. 2029); H.R. 5325, Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2017, and Zika Response and Preparedness Act; Other Labor, Health and Human Services Appropriations (no bills introduced); S. 1413, FDA User Fee Protection Act; FDAs Changes Being Effected Rule;
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL BACHNER | — |
| MICHAEL D BOYD | — |
| JOHN P. FORD | — |
| HEATHER STRAWN | — |
Taxation/Internal Revenue Code TAX
Administrations Tax Reform and 2015 Budget Proposals; Senate and House Committee Tax Reform Proposals; H.R. 5278, PROMESA; Puerto Rican Economy and Debt Relief Proposals (no bills introduced); Proposals to reform domestic and international tax structures (no bills introduced);
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL BACHNER | — |
| MICHAEL D BOYD | — |
| JOHN P. FORD | — |
| ANDREW KAPLAN | — |
| STEPHEN SCANGO | — |
| HEATHER STRAWN | — |
Medicare/Medicaid MMM
Policies to enhance patient access to medicines in Medicaid; Policies to enhance patient access to medicines in Medicare; H.R. 2298, Medicare Patient Safety and Drug Abuse Prevention Act; H.R. 2914, Promoting Integrity in Medicare Act; H.R. 1190 & S. 141, Protecting Seniors' Access to Medicare Act of 2015 H.R. 2925, Strengthening Medicare Anti-Fraud Measures Act; H.R. 3061 & S. 31, Medicare Prescription Drug Price Negotiation Act of 2015; H.R. 1102 & S. 117, Medicare Prescription Drug Price Negotiation Act; H.R. 5122, To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models; Medicare payment proposals (MedPAC); Medicare Access and CHIP Reauthorization Act (MACRA);
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL BACHNER | — |
| MICHAEL D BOYD | — |
| JOHN P. FORD | — |
| ANDREW KAPLAN | — |
| STEPHEN SCANGO | — |
| HEATHER STRAWN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.